Immuron Reports Record Revenue Exceeding AU$2 million for the FY18 year
July 25, 2018 10:00 ET
|
Immuron Limited
Key Highlights: Global Immuron Ltd sales revenue reached an AU$2million milestone continuing its upward trend and enjoying a 29% sales increase compared to FY17.US Travelan® sales continue to exceed...
Immuron Announces it has Received a European Patent Grant for NASH treatment
July 24, 2018 06:30 ET
|
Immuron Limited
MELBOURNE, Australia, July 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally...
US Department of Defense Research Collaboration Moves Forward
July 24, 2018 06:28 ET
|
Immuron Limited
Key Highlights: Three US Defense Health funded research projects on Travelan® successfully completedStudies commissioned by the US Department of Defense to evaluate Travelan®’s ability to...
Immuron Reports Significant Alleviation of Colitis Symptoms in Preclinical Program
May 07, 2018 21:43 ET
|
Immuron Limited
MELBOURNE, Australia, May 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and commercializing orally...
UPDATE -- Immuron Commences US Non-Deal Institutional Investor Roadshow
March 13, 2018 02:15 ET
|
Immuron Limited
MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC)(NASDQ:IMRN) is pleased to release to shareholders and investors its...
Immuron Commences US Non-Deal Institutional Investor Roadshow
March 12, 2018 08:17 ET
|
Immuron Limited
MELBOURNE, Australia, March 12, 2018 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company Immuron Limited (ASX:IMC)(NASDQ:IMRN) is pleased to release to shareholders and investors its...
Immuron Limited Issues Correction to Misleading Halt Announcement Headline
March 07, 2018 17:06 ET
|
Immuron Limited
MELBOURNE, Australia, March 07, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) (the “Company”) wishes to correct a misleading halt announcement released over the wire yesterday. ...
Travelan® Revenue Grows Significantly in US and Australia
February 16, 2018 09:30 ET
|
Immuron Limited
Key Highlights: Immuron’s flagship product Travelan® reports revenue in excess of AUS$914K for first 6mths of FY2018 Travelan® US experienced a 250% increase in sales year over year reaching...
Immuron Enrols First Patients in Clinical Study of IMM-529 for Treatment of Clostridium Difficile Infection (CDI)
January 31, 2018 09:30 ET
|
Immuron Limited
Key Highlights: First patients enrolled in Immuron’s IMM-529 clinical study at Hadassah Medical Center in Israel Trial will treat 60 confirmed patients over 28 days to evaluate safety and efficacy of...
US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella
January 29, 2018 09:20 ET
|
Immuron Limited
Key Highlights: The research program was performed by the U.S. Department of Defense (DoD) and was conducted by the Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences...